Presentation ESC 2025 Duration of Dual Antiplatelet Therapy in Acute Coronary Syndromes: The DUAL-ACS Trial Presenter: David Newby September 03, 2025
Presentation ESC 2025 Randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery: The NEWTON-CABG CardioLink-5 Trial Presenter: Subodh Verma September 01, 2025
Presentation ESC 2025 Dual or single antiplatelet therapy after coronary artery bypass grafting in patients with acute coronary syndrome: The TACSI trial Presenter: Anders Jeppsson September 01, 2025
Presentation ESC 2025 Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI: The TAILORED-CHIP Randomized Clinical Trial Presenter: Duk-Woo Park August 31, 2025
Presentation ESC 2025 SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease Presenter: Mårten Falkenberg, Joakim Nordanstig August 31, 2025
Presentation ESC 2025 Helicobacter Pylori Screening after Acute Myocardial Infarction: The Cluster Randomized Crossover HELP-MI-SWEDEHEART Trial Presenter: Robin Hofmann August 31, 2025
Presentation ESC 2025 Vericiguat in ambulatory patients with chronic heart failure with reduced ejection fraction: Results of the VICTOR trial Presenter: Faiez Zannad August 30, 2025
Presentation ESC 2025 PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET trial Presenter: Pedro A. Lemos August 30, 2025
Presentation ESC 2025 Mavacamten in Symptomatic Nonobstructive Cardiomyopathy: Primary results of the ODYSSEY-HCM Trial Presenter: Milind Y Desai August 30, 2025
Presentation ESC 2025 Essence-TIMI 73b: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk Presenter: Brian Bergmark August 30, 2025
Presentation ESC 2025 DAPA ACT HF – TIMI 68: Dapagliflozin in Patients Hospitalized for Heart Failure Presenter: David D. Berg August 30, 2025
Presentation ESC 2025 DANCAVAS 2: Screening and intervention to prevent cardiovascular disease and death Presenter: Axel Diederichsen August 30, 2025
Presentation ESC 2025 BETAMI-DANBLOCK: Randomized Discontinuation of Beta-blockers After Myocardial Infarction in Patients Without Heart Failure Presenter: Eva Prescott, Dan Atar August 30, 2025
Presentation ESC 2025 Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction: REBOOT Presenter: Borja Ibanez August 30, 2025
Presentation ESC 2025 AQUATIC: Assessment of Quitting versus Using Aspirin Therapy In patients with stabilized Coronary artery disease after stenting who require long-term oral anticoagulation Presenter: Martine Gilard August 30, 2025
Presentation ESC 2025 ABC-AF study: Pragmatic registry-based randomised controlled trial of personalised treatment to reduce stroke or death in atrial fibrillation Presenter: Jonas Oldgren August 30, 2025
Presentation ESC 2025 POTCAST: A Randomized Controlled Trial Showing Arrhythmia Prevention Using Targeted Plasma Potassium Levels in ICD Patients Presenter: Henning Bundgaard August 29, 2025
Presentation ESC 2025 DOUBLE-CHOICE: A 2x2 Randomized Trial of Peri-interventional Anesthesia Strategies and Self-Expanding Valve Types in Patients Undergoing Transcatheter Aortic Valve Implantation Presenter: Mohamed Abdel-Wahab August 29, 2025
Presentation ESC 2025 AMALFI: Active Monitoring for Atrial Fibrillation: A randomized controlled trial of remote screening for asymptomatic atrial fibrillation Presenter: Rohan Wijesurendra August 29, 2025
Presentation ESC 2024 The SHAM-PVI Study: A randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation Presenter: Rick Veasey September 02, 2024